You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Surface-covering gels for broad-spectrum antimicrobial protection following open

    SBC: Sonoran Biosciences, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): About 3-4% of all fractures are estimated to be open fractures, where the fracture is exposed through defects in the skin and soft tissues. This equates to about 250,000 open fractures in the United States annually. Open fractures present a high risk of infection. Infection results in considerable financial burden to both the patient an healthcare system, requ ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Orally available transition state inhibitors for triple negative breast cancer

    SBC: Nanometics LLC            Topic: NCI

    Problem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer

    SBC: CUREFAKTOR PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Non-ATP competitive inhibitors of cyclin dependent kinases as cancer therapeutics

    SBC: PPI PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): As cancer is one of the leading causes of death in the United States with some sub-types remaining essentially untreatable, expansion of available drug targets will provide significant new options for the development ofmore effective antineoplastic agents. The major goal of this project is to apply a unique drug discovery strategy to cancer drug development. Th ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Modified RNA tools and diagnostics for drug abuse

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Project Summary/Abstract RNA modifications are numerous, and range from simple methylation to complex changes such as addition of aminoacylcarbamoyl moieties. These modifications and, the levels at which are present, are emerging as important regulators of biological processes, and perturbations such as chemical or drug exposure can alter the patterns of specif ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Mucins in the Diagnosis and Prognosis of Pancreatic Diseases

    SBC: Sanguine Diagnostics And Therapeutics, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Due to its asymptomatic nature and lack of methods for early detection, gt 80% of pancreatic cancer (PC) patients present with an unresectable primary tumor with distant metastasis at the time of diagnosis. While the overall 5 year survival rate of pancreatic cancer is dismal, significantly better outcomes have been reported for smaller tumors detected at an e ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Science Take-Out Kits for Environmental Health Education

    SBC: Science Take-Out, LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Nearly percent of death and disease worldwide is linked to environmental factors WHO therefore it is critical that the general public has basic understanding of how the environment affects their health and how they might protect themselves against environmental exposures Unfortunately environmental health content is typically covered on a very ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Using Structuring Interacting RNAs (sxRNAs) as microRNA Inhibitors

    SBC: HocusLocus Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): We propose developing a trans-molecular RNA-switch for scientists to negatively affect the activity of endogenous microRNA for use as a molecular tool or therapeutic, an anti-miR. Since the discovery of miRNA, the creation of effective anti-miRs has been important, first to study and verify miRNA interactions, and, secondly, as a therapeutic tool. But, creating ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government